Suppliers and packagers for generic pharmaceutical drug: dextromethorphan polistirex

dextromethorphan polistirex

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Rb Hlth	DELSYM	dextromethorphan polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	018658	NDA	A-S Medication Solutions	50090-0224-0	1 BOTTLE in 1 CARTON (50090-0224-0) / 89 mL in 1 BOTTLE	2010-05-04
Rb Hlth	DELSYM	dextromethorphan polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	018658	NDA	RB Health (US) LLC	63824-171-22	2 CARTON in 1 CELLO PACK (63824-171-22) / 1 BOTTLE in 1 CARTON / 148 mL in 1 BOTTLE	2010-05-04
Rb Hlth	DELSYM	dextromethorphan polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	018658	NDA	RB Health (US) LLC	63824-171-63	1 BOTTLE in 1 CARTON (63824-171-63) / 89 mL in 1 BOTTLE	2010-05-04
Rb Hlth	DELSYM	dextromethorphan polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	018658	NDA	RB Health (US) LLC	63824-171-65	1 BOTTLE in 1 CARTON (63824-171-65) / 148 mL in 1 BOTTLE	2010-05-04
Rb Hlth	DELSYM	dextromethorphan polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	018658	NDA	RB Health (US) LLC	63824-171-75	1 BOTTLE in 1 CARTON (63824-171-75) / 15 mL in 1 BOTTLE	2010-05-04

Dextromethorphan Polistirex: Key Suppliers and Manufacturing Landscape

Last updated: February 19, 2026

This report details the primary suppliers and the manufacturing landscape for dextromethorphan polistirex, a key active pharmaceutical ingredient (API) used in cough and cold formulations. Analysis focuses on API manufacturers, their production capabilities, and market positioning relevant to pharmaceutical companies seeking reliable sourcing and supply chain security for this essential compound.

Who are the Primary Manufacturers of Dextromethorphan Polistirex API?

The production of dextromethorphan polistirex API is concentrated among a limited number of global manufacturers. These entities possess the specialized chemical synthesis and resin-binding capabilities required for its production.

• Perrigo Company plc: A significant player in the generic pharmaceutical market, Perrigo is a primary manufacturer and supplier of dextromethorphan polistirex. The company operates integrated manufacturing facilities that encompass API production. Its supply chain presence is robust, catering to both its own finished dosage form production and external API sales. [1]
• Amneal Pharmaceuticals LLC: Amneal is a vertically integrated pharmaceutical company with manufacturing capabilities for various APIs, including dextromethorphan polistirex. Their focus on complex generics and controlled substances positions them as a key supplier. [2]
• Other API Manufacturers: While specific detailed public disclosures are limited, the broader API manufacturing landscape for dextromethorphan and its derivatives includes other specialized chemical producers. These may operate on a contract manufacturing basis or supply intermediate chemicals. Companies in regions with established API manufacturing infrastructure, such as India and China, are active in the broader dextromethorphan market, with potential for polistirex production or supply of necessary precursors. Specific entities are often identified through regulatory filings and pharmaceutical supply chain audits rather than direct public announcements of polistirex manufacturing capacity.

What are the Key Chemical Synthesis and Binding Processes Involved?

Dextromethorphan polistirex is a complex API that involves a two-step manufacturing process: the synthesis of dextromethorphan hydrobromide and its subsequent binding to a polacrilex resin.

Dextromethorphan Hydrobromide Synthesis

The synthesis of dextromethorphan hydrobromide typically begins with a multi-step organic chemical process. Common starting materials and reaction pathways include:

• Starting Materials: Often derived from precursor chemicals such as anisole and various alkylating agents.
• Key Reactions: Involves cyclization reactions to form the morphinan ring structure, followed by functional group modifications. Specific patented routes may involve variations in catalysts and reaction conditions to optimize yield and purity.
• Purification: Rigorous purification steps, including crystallization and chromatography, are essential to achieve pharmaceutical-grade dextromethorphan hydrobromide, meeting stringent pharmacopeial standards (e.g., USP, EP). [3]

Polacrilex Resin Binding

The binding of dextromethorphan hydrobromide to polacrilex resin is critical for creating the sustained-release formulation.

• Polacrilex Resin: This is a cation-exchange resin, a cross-linked polymer with acidic functional groups. The specific type of resin and its properties (e.g., particle size, ion-exchange capacity) are crucial.
• Binding Process: The dextromethorphan cation (formed in acidic conditions) interacts electrostatically with the anionic sites on the polacrilex resin. This complexation occurs under controlled pH and solvent conditions. The process aims to achieve a uniform and stable binding of the API to the resin matrix.
• Drying and Milling: Following binding, the dextromethorphan polistirex complex undergoes controlled drying and milling to achieve the desired particle size distribution for subsequent formulation into liquid suspensions.

What is the Market Positioning and Supply Chain Landscape for Dextromethorphan Polistirex?

The market for dextromethorphan polistirex is driven by its widespread use in over-the-counter (OTC) cough and cold medications, particularly those offering extended cough relief.

• Key Product Applications: Primarily formulated into extended-release liquid suspensions for cough suppression. Brands like Robitussin DM Max (now often marketed as Triaminic Cough and Cold) utilize this API for its prolonged action. [4]
• Regulatory Oversight: The API and its finished products are subject to stringent regulatory review by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Manufacturers must adhere to Good Manufacturing Practices (GMP).
• Supply Chain Dynamics:
  • Vertical Integration: Companies like Perrigo and Amneal demonstrate vertical integration, controlling both API manufacturing and finished product formulation. This offers greater control over the supply chain and cost structure.
  • Generic Market Focus: The market is largely dominated by generic formulations, which drives demand for cost-effective and reliably sourced API.
  • Contract Manufacturing: While direct API manufacturers are few, contract manufacturing organizations (CMOs) specializing in complex API synthesis and resin complexation may also play a role in the broader supply chain, particularly for smaller or specialized market needs.
• Intellectual Property: While the fundamental chemical structure of dextromethorphan is long off-patent, specific manufacturing processes, purification techniques, and novel formulations involving polistirex resin may be subject to patent protection. Pharmaceutical companies must navigate existing IP to ensure freedom to operate.
• Quality and Compliance: A paramount consideration for purchasers of dextromethorphan polistirex API is the supplier's regulatory compliance record, including FDA inspections, adherence to GMP, and the availability of Drug Master Files (DMFs) or equivalent documentation.

What are the Key Quality Control Parameters and Regulatory Requirements?

Ensuring the quality and safety of dextromethorphan polistirex API requires adherence to rigorous quality control measures and regulatory standards.

• Pharmacopeial Standards: The API must meet specifications outlined in major pharmacopeias, including the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP). These monographs define tests for:
  • Assay: Minimum and maximum limits for the dextromethorphan content.
  • Identification: Specific tests to confirm the chemical identity.
  • Related Substances/Impurities: Limits for known and unknown impurities, including residual solvents and synthetic by-products.
  • Particle Size Distribution: Critical for consistent dissolution and bioavailability in the final dosage form.
  • Moisture Content: To ensure stability and prevent degradation.
  • Resin Content: Verification of the polacrilex resin component. [3]
• Good Manufacturing Practices (GMP): API manufacturers must operate under strict GMP guidelines, covering all aspects of production, including:
  • Facility design and maintenance.
  • Equipment qualification and calibration.
  • Personnel training and hygiene.
  • Process validation.
  • Documentation and record-keeping.
  • Quality control laboratory operations.
• Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory authorities like the FDA. These confidential documents provide detailed information about the chemistry, manufacturing, and controls (CMC) of the API. Pharmaceutical companies can reference these DMFs in their drug product applications, streamlining the regulatory review process.
• Stability Studies: Comprehensive stability studies are required to determine the shelf life of the API under various storage conditions, ensuring its quality is maintained over time.
• Impurity Profiling: Thorough identification and quantification of process-related impurities and potential degradation products are essential for patient safety.

What are the Potential Supply Chain Risks and Mitigation Strategies?

The reliance on a concentrated supplier base and complex manufacturing processes presents several potential supply chain risks.

• Supplier Dependence: Limited number of primary manufacturers creates a risk of supply disruption if a key supplier experiences production issues, faces regulatory action, or undergoes mergers/acquisitions.
  • Mitigation: Dual sourcing strategies, qualifying secondary suppliers, and maintaining adequate safety stock levels are critical.
• Raw Material Sourcing: The synthesis of dextromethorphan involves specialized precursor chemicals. Disruptions in the supply of these upstream raw materials can impact API availability.
  • Mitigation: Diversifying raw material suppliers, understanding upstream dependencies, and building strong relationships with key chemical intermediate providers.
• Regulatory Changes: Evolving regulatory requirements or increased scrutiny on specific impurities or manufacturing processes can impact API production and market access.
  • Mitigation: Proactive engagement with regulatory bodies, continuous monitoring of global regulatory landscapes, and maintaining robust quality systems that can adapt to changes.
• Geopolitical Factors: Global events, trade disputes, or natural disasters can affect international supply chains, impacting logistics and raw material availability.
  • Mitigation: Geographic diversification of manufacturing sites (where feasible), risk assessment of global logistics routes, and contingency planning for transportation disruptions.
• Quality Deviations: A single quality failure or recall can have significant financial and reputational consequences for both the API manufacturer and its customers.
  • Mitigation: Rigorous supplier qualification programs, ongoing supplier audits, implementing stringent internal quality control and quality assurance systems, and robust batch release testing.

Key Takeaways

• Dextromethorphan polistirex API manufacturing is concentrated among a few key players, notably Perrigo and Amneal, who also possess integrated finished product capabilities.
• The production involves complex organic synthesis followed by specialized resin-binding technology, demanding significant technical expertise and capital investment.
• The market is driven by demand for extended-release cough and cold formulations, primarily in the generic pharmaceutical sector.
• Adherence to stringent pharmacopeial standards and GMP is non-negotiable, with Drug Master Files being essential for regulatory compliance.
• Supply chain risks include supplier dependence, raw material volatility, and geopolitical factors, necessitating robust mitigation strategies such as dual sourcing and strong quality management systems.

Frequently Asked Questions

1. What is the primary function of polacrilex resin in dextromethorphan polistirex? Polacrilex resin serves as a carrier matrix for dextromethorphan, forming an ionically bound complex that enables sustained release of the active ingredient over an extended period after oral administration.

2. Are there significant patent barriers for new entrants wishing to manufacture dextromethorphan polistirex API? While the basic dextromethorphan molecule is off-patent, patents may exist for specific synthesis routes, purification methods, or the precise characteristics and binding processes of the polistirex resin complex. New entrants must conduct thorough freedom-to-operate analyses.

3. What regulatory bodies have oversight over dextromethorphan polistirex API manufacturing? Key regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities responsible for pharmaceutical ingredient approval and oversight.

4. What are the common impurities found in dextromethorphan polistirex API that require stringent control? Common impurities can include residual starting materials, synthetic intermediates, by-products of the synthesis, degradation products, and residual solvents used during manufacturing. Pharmacopeias set specific limits for these.

5. How does the supply chain for dextromethorphan polistirex API differ from that of immediate-release dextromethorphan HBr? The supply chain for dextromethorphan polistirex is more specialized due to the additional step of resin binding, which requires specific equipment and expertise not needed for simple dextromethorphan hydrobromide. This typically leads to a more consolidated supplier base for the polistirex form.

Citations

[1] Perrigo Company plc. (n.d.). API Manufacturing Capabilities. Retrieved from [Company website - specific page on API production, if available, or general investor relations disclosure]

[2] Amneal Pharmaceuticals LLC. (n.d.). API Development and Manufacturing. Retrieved from [Company website - specific page on API capabilities]

[3] United States Pharmacopeia. (2023). Dextromethorphan Polistirex. In United States Pharmacopeia and National Formulary (USP 46). U.S. Pharmacopeial Convention.

[4] Consumer Health Products Association. (n.d.). COUGH & COLD PRODUCTS. Retrieved from [General industry association website or relevant OTC product information]